Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MW150 in mild to moderate Alzheimer's disease
NCT05194163Phase 2Unknown
- Sponsor
- NeuroKine Therapeutics
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MW150 with Placebo (2 arms). Primary endpoints: Drug Safety- Blood tests at 84 days, Drug Safety- Electrocardiographic at 84 days and 2 more. Status: unknown.
02
Drugs
mw150
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05194163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194163.